lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
22,393 rows where issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3528125 | BGR GOVERNMENT AFFAIRS 97f53de5-92ac-485e-8e52-75320aeafe00 | Q1 | BGR GOVERNMENT AFFAIRS | 5357 | NEUROCRINE BIOSCIENCES, INC. | 2026 | first_quarter | PHA | Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-12T09:26:54-05:00 | ||
| 3528127 | BGR GOVERNMENT AFFAIRS 9b25d84e-e453-45cb-a198-0491ca121cd7 | Q1 | BGR GOVERNMENT AFFAIRS | 5357 | WALGREEN CO. | 2026 | first_quarter | PHA | Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2026-01-12T09:36:26-05:00 | ||
| 3327470 | CARD & ASSOCIATES, LLC 61760c0d-5de8-43b5-bc49-a7feb75b0349 | 1T | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2025 | first_quarter | PHA | Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2025 Appropriations Support access to telehealth Monitor and engage on EU & Canadian digital regulatory policies Monitor international trade issues | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 1 | 2025-02-14T08:25:55-05:00 | |
| 3327745 | CHRISTIANACARE 32450824-5cf9-4d39-9638-055fb9abe470 | Q1 | CHRISTIANACARE | 401105790 | CHRISTIANACARE | 2025 | first_quarter | PHA | Issues related to the 340B Drug Pricing Program. | HOUSE OF REPRESENTATIVES,SENATE | 8000 | 0 | 0 | 2025-03-26T12:49:16-04:00 | |
| 3328295 | BUCHANAN INGERSOLL & ROONEY PC 769fe845-fb48-40aa-aa98-725448408b14 | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | AIM IMMUNOTECH INC. | 2025 | first_quarter | PHA | Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-04-02T11:32:24-04:00 | |
| 3328535 | AMERICAN COLLEGE OF CLINICAL PHARMACY 321b12aa-1d40-42ac-b650-110903870be3 | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2025 | first_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2025-04-03T09:13:16-04:00 | |
| 3328877 | AEGIS LLC 09f594e6-84e2-4a80-9272-e6905d783c15 | Q1 | AEGIS LLC | 401108688 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2025 | first_quarter | PHA | Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-04-04T14:22:12-04:00 | |
| 3328879 | AEGIS LLC d4962b4f-e763-492e-a131-8292f7e96b6c | Q1 | AEGIS LLC | 401108688 | TRIS PHARMA, INC. | 2025 | first_quarter | PHA | ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. | HOUSE OF REPRESENTATIVES,Natl Highway Traffic Safety Administration (NHTSA),SENATE | 50000 | 0 | 0 | 2025-04-04T14:22:52-04:00 | |
| 3329043 | RED+BLUE STRATEGIES d97d6f2c-29fd-4968-b5e6-8e7eedddf4b7 | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2025 | first_quarter | PHA | H.R. 1968 - Full Year Continuing Resolution - Issues related to funding within the Department of Health and Human Services and its agencies for coverage of prescription medications. S. 891 - The Bipartisan Health Care Act - Policies impacting the treatment of pharmacy benefit managers in prescription medication supply chains. Issues related to pharmacy benefit managers in government and commercial insurance sectors. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-05T12:56:03-04:00 | |
| 3329595 | REPUBLIC CONSULTING, LLC 90718524-5710-4e4e-9cd2-d7b80d973af7 | Q1 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2025 | first_quarter | PHA | monitor health data policy. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-04-07T16:33:02-04:00 | |
| 3329613 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER faf151aa-f701-489b-8f7a-1f6d35167bd1 | Q1 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2025 | first_quarter | PHA | 340b | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 38650 | 0 | 0 | 2025-04-07T16:48:26-04:00 | |
| 3330003 | MANATOS & MANATOS f5fba584-a543-46a5-813a-949353c72440 | Q1 | MANATOS & MANATOS | 23634 | VANDA PHARMACEUTICALS INC | 2025 | first_quarter | PHA | FDA approval of specific medical drugs | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2025-04-08T15:20:18-04:00 | ||
| 3330037 | MCDERMOTT+ LLC 11b36535-6081-4b10-8ec3-6bf378285343 | Q1 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2025 | first_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in thefederal discount drug purchasing program. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-04-08T15:54:40-04:00 | |
| 3330402 | TRUSYNERGY 37d9c5f9-a8b4-465e-9ce1-57321780d7b6 | Q1 | TRUSYNERGY | 401107715 | BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) | 2025 | first_quarter | PHA | Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-04-09T12:49:56-04:00 | |
| 3330495 | PUBLIC CITIZEN 5bef0670-8d38-40ec-b45b-5a06061e61a8 | Q1 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2025 | first_quarter | PHA | anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions. | HOUSE OF REPRESENTATIVES,SENATE | 76570 | 0 | 0 | 2025-04-09T14:04:19-04:00 | |
| 3331016 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) baf857bf-ce81-49fc-9acb-d7c54d2afdf7 | Q1 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) | 401105192 | CVS HEALTH | 2025 | first_quarter | PHA | Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. | HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2025-04-10T13:19:43-04:00 | |
| 3331017 | FLYNN & ASSOCIATES, INC. c103dfca-1963-4145-9a35-d29d46ea1a23 | 1T | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2025 | first_quarter | PHA | PBM Price Reforms, | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 1 | 2025-04-10T13:22:32-04:00 | |
| 3331442 | DAVE KOLBE CONSULTING 3a2c3049-4b50-4c1d-bfa9-d575e3bb18d4 | Q1 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2025 | first_quarter | PHA | H.R. 1492 (EPIC Act) - Asking members to co-sponsor HR 1492 which fixes the Inflation Reduction Act's small molecule "pill penalty" to ensure continued R&D investments into small molecule medicines. | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2025-04-10T17:14:49-04:00 | |
| 3331479 | NATIONAL GROCERS ASSOCIATION 469f73a8-ff48-4e62-b346-85129a9a19d5 | Q1 | NATIONAL GROCERS ASSOCIATION | 27924 | NATIONAL GROCERS ASSOCIATION | 2025 | first_quarter | PHA | Pharmacy Direct and Indirect Remuneration Fee Reform Pharmacy Benefit Manager Transparency Pharmacy Quality Measures Standardized pharmacy performance measures Any Willing Pharmacy | HOUSE OF REPRESENTATIVES,SENATE | 229505 | 0 | 0 | 2025-04-10T17:31:13-04:00 | |
| 3331499 | MASON STREET CONSULTING, LLC 9ec5c1e7-1cb2-4508-991f-5c6dadf7140b | Q1 | MASON STREET CONSULTING, LLC | 401105150 | CAPITAL RX INC. | 2025 | first_quarter | PHA | PBM Reform. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-10T18:13:35-04:00 | |
| 3331503 | MASON STREET CONSULTING, LLC 36d5a403-ed47-4634-ba70-e9f0f4ccd5c8 | Q1 | MASON STREET CONSULTING, LLC | 401105150 | DOMPE US INC. | 2025 | first_quarter | PHA | Tariffs on orphan drugs. | Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),White House Office | 30000 | 0 | 0 | 2025-04-10T18:19:09-04:00 | |
| 3331558 | MR. H.R. BERT PENA 82ae1e25-cff8-46a8-8516-7473a99e43f6 | Q1 | MR. H.R. BERT PENA | 400323519 | MARGO RX LLC(DBA RICHARD'S PHARMACY) | 2025 | first_quarter | PHA | PBM issues | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 0 | 0 | 2025-04-11T07:42:37-04:00 | ||
| 3332131 | TARPLIN, DOWNS & YOUNG, LLC b0afc1d3-c0ae-414e-a209-ddef7a33fd87 | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2025 | first_quarter | PHA | General issues related to access to medication assisted treatment Implementation of Public Law 113-54 (DSCSA) | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 80000 | 0 | 0 | 2025-04-11T15:16:13-04:00 | |
| 3332172 | HOLLAND & KNIGHT LLP f3b8fdec-5485-4ce8-b275-1726fb0a8979 | Q1 | HOLLAND & KNIGHT LLP | 18466 | VIATRIS INC | 2025 | first_quarter | PHA | Safe Act of 2025; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-11T16:05:38-04:00 | |
| 3332307 | INDEPENDENT PHARMACY COOPERATIVE 7317b8e6-8a31-4137-b762-db09a46de00a | Q1 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2025 | first_quarter | PHA | IPC supports Protecting Pharmacies in Medicaid Act (S.927) IPC supports Patients Before Middlemen Act (S 882). IPC supports Continuing Resolution (H.R. 1968) ECAPS provision CMS Implementation of drug provisions of the IRA 2022-including the drug negotiation provision with changes. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-04-12T11:44:20-04:00 | |
| 3332634 | STUMPTOWN STRATEGIES 30e28f94-08b0-419a-9f6f-d8fa45b6174a | Q1 | STUMPTOWN STRATEGIES | 401106433 | PRIME THERAPEUTICS | 2025 | first_quarter | PHA | HR 2214 DRUG Act Delinking, PBM Issues | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-04-13T13:40:30-04:00 | |
| 3332650 | GOVERNMENT COUNSEL, LLC 38bf3b17-99a4-4cf2-9fba-e00d6884b65f | Q1 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2025 | first_quarter | PHA | Implementation of Public Law 113-54 (DSCSA). | HOUSE OF REPRESENTATIVES | 60000 | 0 | 0 | 2025-04-13T13:53:44-04:00 | |
| 3332898 | WAKEFERN FOOD CORP. dbe02749-26f2-4cf3-8772-fe0a6bb24131 | Q1 | WAKEFERN FOOD CORP. | 400588798 | WAKEFERN FOOD CORP. | 2025 | first_quarter | PHA | Protecting Pharmacies In Medicaid Act (S. 927) Patients Before Middlemen Act (S. 882) Prescription Drug Transparency and Affordability Act (No bill number yet) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2025-04-14T09:03:43-04:00 | ||
| 3333389 | KOUNTOUPES DENHAM CARR & REID, LLC 97a00079-a2c2-4d80-85de-866a379563e5 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | AMERICAN KRATOM ASSOCIATION | 2025 | first_quarter | PHA | Issues related to Food and Drug Administration regulatory and consumer access. Issues related to H.R. 5905, Federal Kratom Consumer Protection Act, and the Fiscal Year 2026 Agriculture Appropriations bills. | HOUSE OF REPRESENTATIVES | 50000 | 0 | 0 | 2025-04-14T12:17:24-04:00 | |
| 3333530 | KOUNTOUPES DENHAM CARR & REID, LLC eb64a006-01a8-4014-9d4d-89de8be2e62e | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2025 | first_quarter | PHA | Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-04-14T13:54:26-04:00 | |
| 3333562 | KOUNTOUPES DENHAM CARR & REID, LLC 29faf07b-aa29-4154-a82f-27cbcd2cf2d5 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2025 | first_quarter | PHA | General issues related to over-the-counter (OTC) pharmaceutical supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-04-14T14:09:21-04:00 | |
| 3333596 | KOUNTOUPES DENHAM CARR & REID, LLC 0499739e-1b04-4d9a-b2b9-fbc48ac5dd7c | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2025 | first_quarter | PHA | Issues related to pharmaceutical supply chains. | HOUSE OF REPRESENTATIVES | 60000 | 0 | 0 | 2025-04-14T14:23:49-04:00 | |
| 3334406 | CORNERSTONE GOVERNMENT AFFAIRS, INC. a67dc24f-7edf-4bd4-88cb-f4234bf63075 | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2025 | first_quarter | PHA | Health-related issues including reimbursement, research, public-health & clinical care. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2025-04-15T09:58:28-04:00 | |
| 3334574 | POLSINELLI PC 50c4ef46-8e7b-4694-bcd9-eff72136bdf8 | Q1 | POLSINELLI PC | 314911 | RESQ PHARMA | 2025 | first_quarter | PHA | FDA Regulatory Issues | HOUSE OF REPRESENTATIVES | 10000 | 0 | 0 | 2025-04-15T10:50:49-04:00 | |
| 3335236 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 8be03bc0-0ca4-4516-967b-4a31157731c9 | Q1 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2025 | first_quarter | PHA | - The Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 201227 | 0 | 0 | 2025-04-15T15:06:26-04:00 | |
| 3335317 | THE ROTUNDA GROUP LLC f73e092f-e3d7-4177-9e45-1abb3114d6c6 | Q1 | THE ROTUNDA GROUP LLC | 401104124 | HEALTHPLAN DATA SOLUTIONS, INC. | 2025 | first_quarter | PHA | pharmacy benefit reform; pharmacy payment integrity | HOUSE OF REPRESENTATIVES | 10000 | 0 | 0 | 2025-04-15T15:22:10-04:00 | |
| 3335323 | ICE MILLER LLP f478b02c-a775-4da8-adae-795a0841287c | Q1 | ICE MILLER LLP | 67854 | COALITION FOR RESPONSIBLE COMPOUDING INC. | 2025 | first_quarter | PHA | Educating Congress and the Executive Branch about compounding procedures and standards. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-04-15T15:24:33-04:00 | |
| 3335794 | FORBES-TATE 92be7aba-7d71-4c05-8bfe-5f137167a553 | Q1 | FORBES-TATE | 400976792 | PHRMA | 2025 | first_quarter | PHA | Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2025-04-15T18:48:05-04:00 | |
| 3335912 | FORBES-TATE a89c3bd6-a4cd-4d91-b48e-8aaa972980ab | Q1 | FORBES-TATE | 400976792 | INDEPENDENT PHARMACY COOPERATIVE | 2025 | first_quarter | PHA | Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-04-15T21:14:52-04:00 | |
| 3335948 | BROWNSTEIN HYATT FARBER SCHRECK, LLP e6e83437-9dc5-43d7-8e75-6cce2d72f3f5 | Q1 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | WALGREEN CO. | 2025 | first_quarter | PHA | Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare Issues regarding immunization and vaccines | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-15T22:25:11-04:00 | |
| 3335982 | PENN AVENUE PARTNERS 1095b415-7af2-4cd9-88bb-43d82d912eba | Q1 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2025 | first_quarter | PHA | Regulatory and legislative issues impacting Alkermes. Appropriations. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 60000 | 0 | 0 | 2025-04-16T04:40:41-04:00 | |
| 3336043 | PENN AVENUE PARTNERS cca0fa42-12e9-481d-a0d8-2414681981d7 | Q1 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2025 | first_quarter | PHA | Pharmacy benefit related issues. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 90000 | 0 | 0 | 2025-04-16T06:57:23-04:00 | |
| 3336079 | TAUZIN STRATEGIC NETWORKS 01b636fd-2b49-43fd-ad28-3c8c604d8a13 | Q1 | TAUZIN STRATEGIC NETWORKS | 400786367 | RAZORMETRICS | 2025 | first_quarter | PHA | Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 37500 | 0 | 0 | 2025-04-16T08:18:26-04:00 | |
| 3336289 | BOLD STRATEGIES, LLC b098a7f3-9d02-4b3b-bbba-56793e1dede2 | Q1 | BOLD STRATEGIES, LLC | 401104653 | MORRIS & DICKSON CO., LLC | 2025 | first_quarter | PHA | Prescription drug issues generally. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-04-16T10:13:05-04:00 | |
| 3336768 | ICE MILLER LLP 8eb6cd59-f4ec-4bf8-847f-85daea035623 | 1A | ICE MILLER LLP | 67854 | COALITION FOR RESPONSIBLE COMPOUDING INC. | 2025 | first_quarter | PHA | Educating Congress and the Executive Branch about compounding procedures and standards. | Food & Drug Administration (FDA) | 10000 | 0 | 0 | 2025-04-16T12:00:16-04:00 | |
| 3336858 | TRAVERE THERAPEUTICS 1609b792-82d5-4214-b33b-d9df2e0fbc5a | Q1 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2025 | first_quarter | PHA | HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act) | HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2025-04-16T12:25:40-04:00 | |
| 3336930 | FAEGRE DRINKER BIDDLE & REATH LLP 9b7d7737-5189-44e9-924b-548750177d97 | Q1 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | NATIONAL ASSOCIATION OF BOARDS OF PHARMACY | 2025 | first_quarter | PHA | Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-04-16T12:53:05-04:00 | |
| 3336995 | HEALTHSPERIEN c0d2a6bd-3e89-4b84-8c48-8c640d7ff13f | Q1 | HEALTHSPERIEN | 401103150 | EXACT CARE PHARMACY | 2025 | first_quarter | PHA | Advocate for codifying definition for long-term care pharmacy. (S. 1574), Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2025-04-16T13:07:30-04:00 | ||
| 3337244 | RICCHETTI INCORPORATED 16a946c2-a490-46f3-906e-626831af6b1e | 1T | RICCHETTI INCORPORATED | 62778 | EISAI, INC. | 2025 | first_quarter | PHA | Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2025-04-16T14:22:33-04:00 | |
| 3337248 | RICCHETTI INCORPORATED b032a4f8-e07a-48ed-b058-abb07e78234c | Q1 | RICCHETTI INCORPORATED | 62778 | IPSEN BIOPHARMACEUTICALS, INC. | 2025 | first_quarter | PHA | Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-04-16T14:23:55-04:00 | |
| 3337461 | ELI LILLY AND COMPANY abca769c-cbf5-4784-8de6-1053bffd86f8 | Q1 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2025 | first_quarter | PHA | Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act | HOUSE OF REPRESENTATIVES,SENATE | 3350000 | 0 | 0 | 2025-04-16T15:02:51-04:00 | |
| 3337472 | NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 0eda37d8-70df-4eee-8875-6e1f22f28074 | Q1 | NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) | 28264 | NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) | 2025 | first_quarter | PHA | Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-16T15:06:21-04:00 | |
| 3337531 | E3 STRATEGIC CONSULTING GROUP 4e26ad16-7cb2-485c-855a-36aa1fa8a8f6 | Q1 | E3 STRATEGIC CONSULTING GROUP | 401104104 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2025 | first_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, and employment issues, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-16T15:18:21-04:00 | |
| 3337686 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) bced6e52-094b-4871-8579-c31eb2503d4f | Q1 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2025 | first_quarter | PHA | Opioid Abuse - General issues related to access to medication assisted treatment Implementation of Public Law 113-54 (DSCSA) | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 508963 | 0 | 0 | 2025-04-16T15:52:05-04:00 | |
| 3337734 | THEGROUP DC, LLC 961cacbe-311a-4b8b-acc0-5e2e12409a28 | 1T | THEGROUP DC, LLC | 401103834 | GILEAD SCIENCES, INC. | 2025 | first_quarter | PHA | General advocacy surrounding pharmaceuticals and drug development. | HOUSE OF REPRESENTATIVES | 60000 | 0 | 1 | 2025-04-16T16:03:16-04:00 | |
| 3337818 | SAREPTA THERAPEUTICS, INC. 434d4074-3afb-46b9-ad6e-c8eab2729ae3 | Q1 | SAREPTA THERAPEUTICS, INC. | 401103510 | SAREPTA THERAPEUTICS, INC. | 2025 | first_quarter | PHA | Issues related to the Inflation Reduction Acts prescription drug provisions | HOUSE OF REPRESENTATIVES,SENATE | 320000 | 0 | 0 | 2025-04-16T16:18:06-04:00 | |
| 3338035 | MR. BRIAN KELLY f52ac711-dd2d-4338-aaf0-2964bc3821d5 | 1A | MR. BRIAN KELLY | 40024191 | TAKEDA PHARMACEUTICAL COMPANY | 2025 | first_quarter | PHA | Trade and tariffs | Commerce, Dept of (DOC),U.S. Trade Representative (USTR),White House Office | 10000 | 0 | 0 | 2025-04-16T16:46:12-04:00 | |
| 3338431 | ASSOCIATION FOR ACCESSIBLE MEDICINES a2932449-d86b-4bf4-8b97-72e156da7087 | Q1 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 16032 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2025 | first_quarter | PHA | Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 650000 | 0 | 0 | 2025-04-16T18:37:15-04:00 | |
| 3338630 | BALLARD PARTNERS c683cca6-ddce-4647-bbc8-6c6fdd480fd1 | Q1 | BALLARD PARTNERS | 401104288 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2025 | first_quarter | PHA | Lower healthcare costs, pharmacy coverage and reimbursement issues, (does not include any PBM issues). | Health & Human Services, Dept of (HHS),White House Office | 90000 | 0 | 0 | 2025-04-16T22:00:40-04:00 | |
| 3338913 | FORBES-TATE 819d7189-ab54-4932-a69d-96da7110e473 | Q1 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2025 | first_quarter | PHA | Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-04-17T08:45:21-04:00 | |
| 3339177 | BROYDRICK & ASSOCIATES da9107d7-d633-4432-a07f-227fa84c2ac6 | Q1 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2025 | first_quarter | PHA | Funding new drug for PTSD and COVID 19, BARDA appropriations. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-04-17T09:49:39-04:00 | |
| 3339240 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH a1c36a61-212f-42ef-880b-850b9cc62eb4 | Q1 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2025 | first_quarter | PHA | Increasing the affordability and accessibility of treatments for Parkinsons disease. | HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2025-04-17T10:00:34-04:00 | |
| 3339426 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 016d8cea-79f7-4558-9aa5-75df9a48ba25 | Q1 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2025 | first_quarter | PHA | Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). Issues related to 340B program nondiscrimination and contract pharmacy arrangements (generally, no specific legislation). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 220000 | 0 | 0 | 2025-04-17T10:32:28-04:00 | |
| 3339603 | UNIVERSITY OF IOWA 169b3116-4c6a-4588-887c-31bce7cfc076 | Q1 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2025 | first_quarter | PHA | N/A | HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2025-04-17T10:55:49-04:00 | |
| 3339803 | MEHLMAN CONSULTING, INC. 0479277a-9c18-4f03-adb0-8c4d56737d17 | Q1 | MEHLMAN CONSULTING, INC. | 284950 | AARP, INC. | 2025 | first_quarter | PHA | Issues related to the cost of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T11:23:27-04:00 | |
| 3339854 | MEHLMAN CONSULTING, INC. 82aaa504-babd-453b-9df1-5a812fdc9634 | Q1 | MEHLMAN CONSULTING, INC. | 284950 | AMERICA'S HEALTH INSURANCE PLANS | 2025 | first_quarter | PHA | Prescription drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2025-04-17T11:26:42-04:00 | |
| 3339960 | MEHLMAN CONSULTING, INC. 53b42279-ea31-400c-9267-16481abb0e8b | Q1 | MEHLMAN CONSULTING, INC. | 284950 | ASSOCIATION OF ACCESSIBLE MEDICINES | 2025 | first_quarter | PHA | Issues related to pharmaceutical manufacturing supply chain. | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2025-04-17T11:32:58-04:00 | |
| 3340030 | MEHLMAN CONSULTING, INC. d245f276-bcba-45e2-9ea6-211ce212ca15 | Q1 | MEHLMAN CONSULTING, INC. | 284950 | BLUE CROSS BLUE SHIELD MICHIGAN | 2025 | first_quarter | PHA | Issues related to prescription drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-04-17T11:38:23-04:00 | |
| 3340035 | MEHLMAN CONSULTING, INC. 5d54af2f-17e7-4606-b51d-e74e4980f82a | Q1 | MEHLMAN CONSULTING, INC. | 284950 | BLUE SHIELD OF CALIFORNIA | 2025 | first_quarter | PHA | Issues related to prescription drug pricing and transparency. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T11:39:04-04:00 | |
| 3340083 | MEHLMAN CONSULTING, INC. 01e04265-4c25-42a7-890b-286c000310a7 | Q1 | MEHLMAN CONSULTING, INC. | 284950 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | 2025 | first_quarter | PHA | Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2025-04-17T11:41:28-04:00 | |
| 3340147 | BURRELL INTERNATIONAL GROUP LLC 848e9fc9-57cc-4a92-b58f-d878d406c25b | Q1 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | TONIX PHARMACEUTICALS HOLDING CORP. | 2025 | first_quarter | PHA | LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY26 Defense Appropriation for broad-spectrum antivirals, FY26 LHHS for Long COVID and cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2025-04-17T11:45:34-04:00 | |
| 3340162 | BURRELL INTERNATIONAL GROUP LLC 9b21a77d-a3b3-4a6c-9f35-efb723efc8f0 | Q1 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | SHIONOGI INC. | 2025 | first_quarter | PHA | FY26 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-04-17T11:46:12-04:00 | |
| 3340182 | MEHLMAN CONSULTING, INC. baa6f7ab-d16e-4b91-b68f-ba3cb50b1b4b | Q1 | MEHLMAN CONSULTING, INC. | 284950 | ELEVANCE HEALTH, INC. | 2025 | first_quarter | PHA | Prescription Drug Pricing. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2025-04-17T11:47:42-04:00 | |
| 3340498 | WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH cea4dd17-7277-4599-94cf-fd914509034f | Q1 | WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH | 401107274 | WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH | 2025 | first_quarter | PHA | Any bills or provisions related to the 340b drug discount program. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2025-04-17T12:30:30-04:00 | |
| 3340529 | DA VINCI GROUP 76d6ec72-7ced-4fef-9a53-8e75ef2d286f | Q1 | DA VINCI GROUP | 11548 | BOESEN & SNOW, LLC | 2025 | first_quarter | PHA | Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-04-17T12:33:58-04:00 | |
| 3340611 | THE HARPLE GROUP, LLC cf3aad43-77f4-485e-b772-fc68e9b6bc07 | Q1 | THE HARPLE GROUP, LLC | 401108916 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA) | 2025 | first_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, and prescription drug pricing Pharmacy Benefit Manager Transparency Act of 2023; Prescription Pricing for the People Act of 2023; HELP Copays Act; Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); Lowering Drug Costs for American Families Act; Protecting Patients Against PBM Abuses Act; The Drug Act; Lower Costs, More Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-04-17T12:42:54-04:00 | |
| 3340766 | MEHLMAN CONSULTING, INC. 6e419229-281f-4547-a572-9754c46564df | Q1 | MEHLMAN CONSULTING, INC. | 284950 | WEDGEWOOD PHARMACY LLC | 2025 | first_quarter | PHA | Issues related to animal drug compounding. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T12:58:11-04:00 | |
| 3341209 | FOLEY & LARDNER LLP 438f7918-d7b8-4399-9d28-fb2f83a51839 | Q1 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2025 | first_quarter | PHA | Issues related to Domestic manufacturing; Issues related to 340B; implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2025-04-17T14:14:43-04:00 | |
| 3341529 | FEROX STRATEGIES 70491116-d60a-4107-8af5-b6e9d89a0cce | Q1 | FEROX STRATEGIES | 401104769 | ELI LILLY AND COMPANY | 2025 | first_quarter | PHA | Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2025-04-17T14:55:11-04:00 | |
| 3341573 | FEROX STRATEGIES 5640a8ab-ff6e-4ab6-9b04-3bcd34d6eeff | Q1 | FEROX STRATEGIES | 401104769 | FRESENIUS KABI USA LLC | 2025 | first_quarter | PHA | General patent issues related to generic and biosimilar industries. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T14:58:14-04:00 | |
| 3341583 | UC HEALTH e34e020d-5ca0-44f3-8deb-f5c2f4bcafeb | Q1 | UC HEALTH | 401103195 | UC HEALTH | 2025 | first_quarter | PHA | 340B | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T14:59:50-04:00 | |
| 3341754 | FOLEY & LARDNER LLP e4f46357-f93d-447b-994c-876b7d3df3c5 | Q1 | FOLEY & LARDNER LLP | 15042 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2025 | first_quarter | PHA | Issues related to manufacturing and pharmaceutical trade. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2025-04-17T15:14:10-04:00 | |
| 3341759 | FEROX STRATEGIES b31b5076-fad5-417f-a717-10cc1d03cd8d | Q1 | FEROX STRATEGIES | 401104769 | VIATRIS INC | 2025 | first_quarter | PHA | Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2025-04-17T15:14:47-04:00 | |
| 3341837 | SIMS STRATEGIES, LLC 17fc3af7-87b4-42fc-a35e-8c723da4b0b9 | Q1 | SIMS STRATEGIES, LLC | 401104546 | GLAXOSMITHKLINE, INC. | 2025 | first_quarter | PHA | Issues related to prescription drugs, vaccines, and Pharmacy Benefit Managers. | SENATE | 40000 | 0 | 0 | 2025-04-17T15:20:19-04:00 | |
| 3341853 | FOLEY & LARDNER LLP 653e0e10-50f4-4051-b02a-78b812bedb03 | Q1 | FOLEY & LARDNER LLP | 15042 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2025 | first_quarter | PHA | Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2025-04-17T15:21:20-04:00 | |
| 3341903 | SUSAN B ANTHONY LIST 05a138f8-0a59-4fc6-89c9-120b78ffa5f3 | Q1 | SUSAN B ANTHONY LIST | 400935704 | SUSAN B ANTHONY LIST | 2025 | first_quarter | PHA | Shield laws; H.R. 685 Support and Value Expectant Moms and Babies Act; Chemical abortion drugs; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; Administration Personnel; Presidential Administration Actions | HOUSE OF REPRESENTATIVES,SENATE | 600000 | 0 | 0 | 2025-04-17T15:24:54-04:00 | |
| 3341977 | HANCE SCARBOROUGH 075918b8-436e-445d-976b-db3c78835d08 | Q1 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2025 | first_quarter | PHA | Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations. HR167, the Patient Access to Urgent Use Compounded Medication Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T15:30:19-04:00 | |
| 3342183 | MASSACHUSETTS MEDICAL SOCIETY eab10a25-427e-4845-88a2-e4a198249c98 | Q1 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2025 | first_quarter | PHA | Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2025-04-17T15:43:22-04:00 | |
| 3342310 | THORN RUN PARTNERS 6a9f7ab0-d270-4266-9e42-19ff783363ab | Q1 | THORN RUN PARTNERS | 400534596 | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2025 | first_quarter | PHA | Pharmaceutical reimbursement issues. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-17T15:55:56-04:00 | |
| 3342371 | THORN RUN PARTNERS 5fc241fd-6067-40d0-96ba-eb596c1bed24 | 1T | THORN RUN PARTNERS | 400534596 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2025 | first_quarter | PHA | Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2025-04-17T16:01:28-04:00 | |
| 3342657 | FOLEY & LARDNER LLP 2dedc5f5-85b1-4bf8-bdba-7b904bc44169 | Q1 | FOLEY & LARDNER LLP | 15042 | FOUNDATION CONSUMER HEALTHCARE LLC | 2025 | first_quarter | PHA | Regulations affecting non-prescription drugs | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 120000 | 0 | 0 | 2025-04-17T16:39:37-04:00 | |
| 3342670 | WINNING STRATEGIES WASHINGTON 1cc6e8a8-18a1-4137-ae41-1da4ff12c591 | Q1 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2025 | first_quarter | PHA | Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2025-04-17T16:41:46-04:00 | |
| 3342815 | SQUIRE PATTON BOGGS 2d4ce428-d748-44df-a47c-e82b94a8cb90 | Q1 | SQUIRE PATTON BOGGS | 30906 | SK AMERICAS, INC. | 2025 | first_quarter | PHA | US pharmaceutical policies. | HOUSE OF REPRESENTATIVES,SENATE | 220000 | 0 | 0 | 2025-04-17T16:57:49-04:00 | |
| 3343262 | KAISER FOUNDATION HEALTH PLAN INC. f3f05e62-fe86-427d-b966-217856860a3c | Q1 | KAISER FOUNDATION HEALTH PLAN INC. | 21027 | KAISER FOUNDATION HEALTH PLAN INC | 2025 | first_quarter | PHA | Legislation and regulation regarding pharmaceutical pricing, coverage and care; retail and inpatient pharmacy operations and the role of pharmacy benefit managers. | HOUSE OF REPRESENTATIVES,SENATE | 3000000 | 0 | 0 | 2025-04-17T19:27:52-04:00 | |
| 3343426 | BALLARD PARTNERS d3c8a27a-243a-48c5-876e-e99ec937d35e | Q1 | BALLARD PARTNERS | 401104288 | THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) | 2025 | first_quarter | PHA | 340B Drug Discount Program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2025-04-17T22:20:40-04:00 | |
| 3343518 | HARMONY BIOSCIENCES 5af98c96-7518-4222-bf7f-7d46696c0b2d | Q1 | HARMONY BIOSCIENCES | 401105020 | HARMONY BIOSCIENCES | 2025 | first_quarter | PHA | H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress) | HOUSE OF REPRESENTATIVES,SENATE | 150000 | 0 | 0 | 2025-04-17T23:19:32-04:00 | |
| 3343703 | VAN SCOYOC ASSOCIATES 818072a9-65a3-468e-95c7-cca4878815dc | Q1 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2025 | first_quarter | PHA | Temperature monitoring technology issues, as follows: Public Law 118-159, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2025 Monitor National Defense Authorization Act for Fiscal Year 2026 Monitor Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2026 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2025-04-18T07:19:17-04:00 | |
| 3343830 | AARP 3df0c399-ae01-430e-b0f7-eb302f64c329 | Q1 | AARP | 1694 | AARP | 2025 | first_quarter | PHA | H. Con. Res. 14/S. Con. Res. 7, the Budget Reconciliation Resolution S. 1096, the Preserving Access to Affordable Generics and Biosimilars Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1040, the Drug Competition Enhancement Act. H.R. 9070/S. 1041, the Affordable Prescriptions for Patients Act. S. 1097, the Interagency Patent Coordination and Improvement Act of 2025. No bill number. Discussed pharmacy benefit managers. S. 527, Prescription Pricing for the People Act of 2025. S. 526, the Pharmacy Benefit Manager (PBM) Transparency Act of 2025. S. 229, the Drug-Price Transparency for Consumers (DTC) Act of 2025. No bill number. Discussed Medicare Part D. No bill number. Discussed cap on out-of-pocket prescription drug costs. No bill number. Discussed the Medicare Prescription Payment Plan. No bill number. Discussed the Medicare drug price negotiation program. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 6630000 | 0 | 0 | 2025-04-18T08:49:09-04:00 | |
| 3344058 | VENABLE LLP 0ba9298b-66eb-47b2-b94d-75dfc1dddda4 | Q1 | VENABLE LLP | 39941 | MEDISCA INC. | 2025 | first_quarter | PHA | FDA policy; matters related to pharmacy compounding | 60000 | 0 | 0 | 2025-04-18T09:31:27-04:00 | ||
| 3344200 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 5b441c67-a7fd-4c9e-beaf-49cf99e827dc | Q1 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2025 | first_quarter | PHA | Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and robustness of biopharmaceutical supply chains | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-18T09:55:14-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);